With the goal of developing a therapeutic pipeline for disorders mediated by mast cells, Allegria Therapeutics, a Basel, Switzerland-based business, has secured USD 3.5 million in seed money.
Investor
Forty51 Ventures
With the money, the business hopes to advance a unique set of patented treatment strategies centered on targets that specifically alter mast cells in order to better meet the requirements of patients.
Allegria focuses on mast cells as mediators of inflammatory and allergy-related disorders, a class of indications that is becoming more and more commonplace globally. In the areas of basic mast cell biology, drug discovery, and preclinical drug evaluation, the company works with Dr. Philipp Starkl, a principal investigator at the Medical University of Vienna, and Prof. Marcus Maurer, managing director of Berlin’s Charité Institute for Allergy Research.
The business also declared Maria van Dongen, PhD, a co-founder, to be its new chief executive officer. Dr. van Dongen has a solid track record in Pharma and a wide range of industrial experience. She had previously worked at Johnson & Johnson, among other companies, where she helped to arrange outside collaborations for projects including finding peptide-based medicines and efficiently targeting RNA processing. She has previously oversaw a number of research and development initiatives, such as the creation of a platform for pharmacological interventions aimed at disease prevention and the discovery of extremely novel orally active broad-spectrum influenza antivirals.
ABOUT ALLEGRIA THERAPEUTICS
Forty51 Ventures established Allegria Therapeutics in Basel, Switzerland in 2023. Allegria aims to transform the treatment landscape for inflammatory illnesses caused by mast cells and allergies by pursuing a unique portfolio of patented therapeutic techniques centered around biological targets.
